Clinical Trial Update: The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating LM-302 with Candonilimab and capecitabine as first-line therapy for CLDN18.2-positive gastric or GEJ adenocarcinoma. The stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Candonilimab
• Capecitabine (Xeloda) (Capecitabine)
• LM-302

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: RECRUITING